Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Mucosal expression profiling in patients with inflammatory bowel disease before and after first infliximab treatment

ABSTRACT: We used microarrays to identify mucosal gene signatures predictive of response to infliximab (IFX) in patients with inflammatory bowel disease (IBD) and to gain more insight into the pathogenesis of IBD. Keywords: drug response and treatment effect Mucosal biopsies were obtained at endoscopy in actively inflamed mucosa from 61 IBD patients (24 ulcerative colitis (UC), 19 Crohn’s colitis (CDc) and 18 Crohn’s ileitis (CDi)), refractory to corticosteroids and/or immunosuppression, before and 4-6 weeks after (except for 1 CDc patient) their first infliximab infusion and in normal mucosa from 12 control patients (6 colon and 6 ileum). The patients were classified for response to infliximab based on endoscopic and histologic findings at 4-6 weeks after first infliximab treatment. Total RNA was isolated from intestinal mucosal biopsies, labelled and hybridized to Affymetrix Human Genome U133 Plus 2.0 Arrays.

ORGANISM(S): Homo sapiens

SUBMITTER: Ingrid Arijs 

PROVIDER: E-GEOD-16879 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Json Xml
altmetric image

Publications

Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment.

Arijs Ingrid I   De Hertogh Gert G   Lemaire Katleen K   Quintens Roel R   Van Lommel Leentje L   Van Steen Kristel K   Leemans Peter P   Cleynen Isabelle I   Van Assche Gert G   Vermeire Séverine S   Geboes Karel K   Schuit Frans F   Rutgeerts Paul P  

PloS one 20091124 11

<h4>Background</h4>Antimicrobial peptides (AMPs) protect the host intestinal mucosa against microorganisms. Abnormal expression of defensins was shown in inflammatory bowel disease (IBD), but it is not clear whether this is a primary defect. We investigated the impact of anti-inflammatory therapy with infliximab on the mucosal gene expression of AMPs in IBD.<h4>Methodology/principal findings</h4>Mucosal gene expression of 81 AMPs was assessed in 61 IBD patients before and 4-6 weeks after their f  ...[more]

Similar Datasets

Transcriptomics Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
2010-01-06 | E-GEOD-14580 | biostudies-arrayexpress
Transcriptomics Transcription profiling of human ulcerative colitis samples reveals a predictive response signature to infliximab treatment in ulcerative colitis
2009-09-05 | E-GEOD-12251 | biostudies-arrayexpress
Transcriptomics Microarray analysis of colonic mucosa biopsies in patients with inflammatory bowel disease
2015-05-27 | E-GEOD-59071 | biostudies-arrayexpress
Transcriptomics DNA methylation of purified intestinal epithelial cells from treatment-naive paediatric IBD patients and controls
2015-09-15 | E-MTAB-3709 | biostudies-arrayexpress
Transcriptomics MUCOSAL EXPRESSION OF GENES PI3, ANXA1, AND VDR DESCRIMINATES CROHN’S DISEASE FROM ULCERATIVE COLITIS IN INFLAMMATORY BOWEL DISEASE PATIENTS
2023-10-27 | GSE222070 | GEO
Proteomics Human colon biopsies (healthy and Ulcerative Colitis) LC-MS/MS
2015-05-26 | PXD001608 | Pride
Transcriptomics Molecular patterns in human ulcerative colitis and correlation with response to infliximab
2014-12-22 | E-GEOD-51785 | biostudies-arrayexpress
Proteomics Human colon biopsies (healthy and Ulcerative Colitis) LC-MS/MS
2017-03-31 | MSV000080833 | MassIVE
Transcriptomics Mucosal expression profiling in patients with inflammatory bowel disease before and after first infliximab treatment
2009-11-03 | GSE16879 | GEO
Proteomics A proteome analysis by LC-MS/MS of human colon mucosal biopsies from gastrointestinal healthy rheumatoid arthritis patients
2016-09-26 | PXD003082 | Pride